Biomarker Scientist, Preclinical Fluid Biomarkers and Occupancy

Lundbeck A/S, H; København; On-site; DKK 582,000 - 800,000; Full time

Job summary

Lundbeck A/S in Copenhagen is seeking a Biomarker Scientist to develop and apply fluid biomarker strategies that inform discovery and translational neuroscience programs. You will design targeted and untargeted bioanalytical workflows for CSF, plasma, blood and brain, using LC-MS/MS, proteomics and peptidomics.

You will lead in vivo pharmacology studies, link exposure to pharmacodynamic readouts, interpret complex data, and drive internal and CRO collaborations.

Qualifications

• PhD in neuroscience, pharmacology, biochemistry, bioanalytical sciences, biomedical sciences or related field.
• Hands-on LC-MS/MS and mass spectrometry-based proteomics experience, including bioanalytical assays in biological matrices.
• Experience designing, planning and executing in vivo pharmacology studies with FELASA B certification or equivalent.
• Understanding of translational biomarkers, PK/PD and target engagement, with strong collaboration skills.

Responsibilities

• Develop and apply fluid biomarker strategies informing critical decisions across discovery and translational neuroscience.
• Plan, lead and interpret in vivo pharmacology studies linking exposure to pharmacodynamic effects.
• Design, qualify and implement targeted and untargeted bioanalytical workflows for CSF, plasma, blood and brain.
• Translate complex data into clear project recommendations and drive internal/external collaborations.

Skills

LC-MS/MS

Mass spectrometry proteomics

In vivo pharmacology studies

PK/PD & target engagement

Scientific leadership

Education

PhD in neuroscience, pharmacology, biochemistry, bioanalytical sciences, biomedical sciences or related field

FELASA B certification or equivalent

Job description

Biomarker Scientist, Preclinical Fluid Biomarkers and Occupancy

Requisition ID: 8230

Location: Copenhagen, Danish Capital Region, DK

Biomarker Scientist, Preclinical Fluid Biomarkers and Occupancy

Can you turn advanced bioanalytical data into decisions that accelerate neuroscience drug discovery? Connect fluid biomarkers with in vivo pharmacology and clinical translation.

Your new role

You will develop and apply fluid biomarker strategies that inform critical decisions across Lundbeck's discovery and translational neuroscience programmes. Using LC-MS/MS, quantitative proteomics, peptidomics and other emerging methods, you will design, qualify and implement targeted and untargeted bioanalytical workflows for CSF, plasma, blood, brain and other relevant tissues. You will plan and lead in vivo pharmacology studies, linking drug exposure, target engagement and pharmacodynamic effects to biological readouts. You will critically interpret complex datasets and translate the findings into clear project recommendations. As scientific lead or Study Director, you will take ownership of internal and external studies, working with discovery, DMPK, translational medicine, clinical biomarkers, CROs and academic partners.

Your future team

You will join our 13-person Preclinical Fluid Biomarkers and Occupancy department at Lundbeck's R&D headquarters in Valby, Copenhagen. Our team brings together scientists, research assistants, laboratory technicians and students to investigate compound effects in mechanistic animal models and measure related fluid biomarker changes. We combine hands‑on science and a translational mindset to generate data that support project decisions.

The position is based in Copenhagen, Denmark.

What you bring to the team

You enjoy solving scientific problems, working across disciplines and turning complex findings into clear recommendations. We are looking for:

• A PhD in neuroscience, pharmacology, biochemistry, bioanalytical sciences, biomedical sciences or a related field.
• Strong hands‑on experience with LC-MS/MS and mass spectrometry‑based proteomics, including the development and qualification of bioanalytical assays in biological matrices.
• Experience designing, planning and executing in vivo pharmacology studies, together with FELASA B certification or equivalent.
• Understanding of translational biomarkers, PK/PD and target engagement, and the communication and collaboration skills to lead studies and work effectively with project teams and external partners.

Our promise to you

Lundbeck offers an inspiring workplace and innovative culture, where our curiosity, accountability and adaptability enable us to transform lives. We want to go faster and further on addressing the big unmet needs of people living with brain disorders. We offer rewarding careers with a mix of exciting tasks and development opportunities that are balanced with initiatives focused on your well‑being.

We need every brain in the game, and at Lundbeck, we are committed to building a workforce that is as diverse as the people we serve. Read more about our commitment at www.lundbeck.com/global/about-us/our-commitment/diversity-and-inclusion.

Annual base salary range: 582 000 - 799 700 DKK gross.

At Lundbeck, we are committed to fair and transparent pay. Please note that the final base salary within the stated range will be based on relevant qualifications, skills, competencies, and level of proficiency as well as internal pay equity.

Applications must be received by 30 November 2026.

We review applications on an ongoing basis and may close the process once we find the right candidate.

Learn more about us at www.lundbeck.com, LinkedIn or Instagram (@h_lundbeck).

#EveryBrainInTheGame

About Lundbeck

At Lundbeck, our most important contribution is easing the burden of the millions of people living with brain disorders. Whether it is migraine, depression, or other brain disorders, patients, their carers, and society as a whole depend on us.

Through cutting edge science and strong partnerships, we develop and market some of the world’s leading treatments, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

The brain health challenge is real. Our commitment is real. Our impact is real.